Executive Director, Global Value, Access & Pricing

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The companys R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team you will join other outstanding Revolutionariesin a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

This position will lead the development and execution of global market access and pricing strategies for one of the key disease areas and work with regions to build resources to support optimal access for pipeline assets. The role ensures that the CDPs and asset positioning is developed with an access strategy and pricing reimbursement perspective that is aligned across all regions. This individual will collaborate closely with the Health Economics and Outcomes Research (HEOR) Medical and Region Market Access teams to align global and regional initiatives and play a key role in business development access addition define the products value narrative/Global Value dossier planning and development guide pricing and reimbursement including net pricing corridors optimal country launch sequence and ensure sustainable access in key global markets. Reporting to the VP Global Value Access and Pricing this role will work cross-functionally to influence long-term growth patient impact and company valuation.

Responsibilities:

Global Value Access & Pricing Strategy

• Formulate and define asset and disease area pricing and reimbursement strategies to support optimal access and reimbursement outcomes across all target regions. This includes asset global pricing architecture and launch sequencing strategy to develop net price corridors reference pricing and value-based designs.

• Craft a differentiatedglobal value propositionand oversee the development of theGlobal Value Dossier (GVD)and payer negotiation materials.

• Work closely with members of the Disease Area Strategy teams to help shape priority clinical development plans and combinations with both RevMed and oncology combination therapy opportunities.

• Design and implement strategic plans to support clinical development programs to ensure study designs endpoints and analyses generate the evidence needed for payer and HTA submissions including seeking systematic HTA advice.

• Identify and assess global market access risks and opportunities integrating them into product strategies and reflecting them in Target Product Profiles (TPPs).

• Partner with Clinical Development and Regulatory Affairs to incorporate payer and patient relevant evidence into clinical development strategies.

• Collaborate closely with the HEOR team to ensure alignment between market access needs and health economic research plans for pipeline assets.

• Engage with Regions to incorporate payer policy insights and global trends into product access strategy.

Launch Readiness & Market Engagement

• Lead global payer research andearly engagement/advice from key HTA bodies(e.g. G-BA NICE HAS AIFA Chuikyo).

• Develop and maintain strong business relationships with key functions responsible for value proposition enablement with a focus on Clinical Commercial Regulatory Medical Affairs and HEOR stakeholders.

• Prepare and submitreimbursement and HTA dossiersin priority markets with clear alignment to clinical and economic evidence plans.

Cross-Functional and Team Leadership

• Partner with Medical Affairs HEOR Regulatory and Clinical to align evidence generation with access and reimbursement needs.

• Build and lead ahigh-performing Global Market Access team and coordinate closely with regional leads and country affiliates.

• Serve as a key leader within the globallaunch team actively contributing to go-to-market planning demand forecasting and gross-to-net-scenario modeling.

Policy Risk & External Engagement

• Monitor and address global policy risks (e.g. IRA international reference pricing transparency laws).

• Represent the company externally withpayers HTA bodies trade associations and policy groups helping shape access environments.

• Coordinate with the U.S. region to align on policy and legislation risks that could impact life cycle management pricing corridors.

Required Skills Experience & Education:

• Bachelors degree required; advanced degree inPharmacy Health Economics Public Health Life Sciences or Businesspreferred (e.g. PharmD PhD MBA).

• Minimum15 yearsof progressive leadership in market access pricing and reimbursement within the biopharma industry.

• Demonstrated successlaunching a first-in-class or specialty therapyin the U.S. and multiple ex-U.S. markets (especially Germany France and Japan).

• Demonstrating the ability to build a new capability and framework to support a Global Market Access commercialization strategy.

• Deep understanding of globalpayer systems and HTA processes including AMNOG Chuikyo NICE and other EU frameworks.

• Experience designing and implementingglobal pricing strategy including value-based pricing launch sequencing and reference pricing mitigation.

• Proven ability to workcross-functionally and influence executive leadershipin a dynamic resource-constrained early-stage company.

Preferred Skills:

• Prior experience withEx-U.S. and U.S. legislation and public policies that impact Global and regional decisions (U.S. IRA MFN EU regulations etc.)

• Familiarity withrare disease or oncology product launches.

• Experience working withexternal vendors consultants and access agenciesto develop payer research modeling and dossier development.

• Strongexecutive presence with the ability to clearly articulate complex value stories to both internal and external stakeholders.

• Experience building or scaling global market access functions in a pre-commercial or newly commercial biotech company.

  #LI-DNI